AZ Laser Studio & Medspa Marks Continued Growth and Commitment to Client-Centered Care
AZ Laser Studio & Medspa in Mesa, AZ, is known for its noninvasive facials and body contouring, which blend clinical care with a luxury spa touch.
Mesa, AZ - May 16, 2025 - AZ Laser Studio & Medspa, founded by Michelle Fox, continues to solidify its reputation as one of Arizona's premier medical spas offering transformative, results-driven services.
As the medspa celebrates significant growth and ongoing success, it remains focused on its client-centered approach, striving to empower individuals to look and feel their best through cutting-edge treatments.
Elevating Non-Invasive Treatments with a Client-First Philosophy
Known for its advanced body contouring services and facials, AZ Laser Studio & Medspa has become a standout in Arizona's crowded wellness landscape.
As demand for non-invasive, personalized care continues to rise, the medspa is seeing an increase in clientele seeking holistic, customized treatments that focus on long-term results.
'We've built a foundation based on trust, professionalism, and truly understanding our clients' needs,' said Michelle Fox, founder of AZ Laser Studio & Medspa. 'Our mission is to offer treatments that provide lasting results, and we're excited to see how people's confidence and self-esteem transform after receiving our services.'
A Rising Star in the Arizona Wellness Community
Since its inception, AZ Laser Studio & Medspa has earned a loyal following in the community, thanks to its dedication to the individual needs of every client. The medspa's success is a testament to its unique approach — blending the latest technology with a deeply personal commitment to client satisfaction.
The studio offers a variety of services, including non-invasive body contouring and facials designed to improve both appearance and skin health.
With Michelle Fox at the helm, clients can expect highly tailored treatments that address everything from aging concerns to skin rejuvenation. Fox's vision is clear: to empower people through a combination of professional expertise and the latest aesthetic technologies.
Body contouring services, in particular, have seen an uptick in popularity as more people look for non-surgical options to achieve their ideal body shape without the need for invasive procedures.
Meanwhile, medical-grade facials are becoming a go-to for those seeking glowing, youthful skin.
Looking Ahead: A Continued Focus on Innovation and Client Care
As AZ Laser Studio & Medspa expands, it remains firmly committed to its founding philosophy of blending medical-grade aesthetics with personalized care.
The medspa is actively exploring new technologies and treatments to further enhance client outcomes while maintaining its emphasis on safety, professionalism, and education.
Looking forward, the medspa plans to introduce additional offerings and potentially expand its reach beyond Mesa, continuing its mission to help individuals feel confident and rejuvenated in their own skin.
'We're excited for the future,' said Fox. 'Our focus is always on our clients' well-being. We listen to their needs, adjust our approach, and strive to exceed their expectations. It's the key to our growth, and we're just getting started.'
About AZ Laser Studio & Medspa
AZ Laser Studio & Medspa, located in Mesa, AZ, offers a variety of aesthetic treatments including body contouring and facials designed to address the unique needs of every client.
With a focus on non-invasive procedures and personalized care, the medspa has quickly become a trusted destination for individuals seeking professional, high-quality treatments. Learn more at AZ Laser Studio & Medspa.
Media Contact
Company Name: AZ Laser Studio & Medspa
Contact Person: Michelle Fox
Email: Send Email
Phone: 4804504809
Address: 1061 N Dobson Rd #108
City: Mesa
State: Arizona 85201
Country: United States
Website: https://azlaserstudiomedspa.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery. Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios in their respective core areas. Quick Take on Recent Acquisitions & Deals Pharma giant Sanofi SNY recently announced that it will acquire Blueprint Medicines for a total deal value of up to $9.5 billion to expand its portfolio in rare immunological disease and add an early-stage pipeline in immunology. The impending acquisition will add Blueprint Medicines' only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi's commercial portfolio. Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BioNTech will also receive $2 billion in non-contingent anniversary payments through 2028. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting other pharma giants as well. In May 2025, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are also being eyed. Last week, Regeneron REGN entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. M&A in Focus in 2025 Consolidation has long been a central focus in the pharma/biotech industry. This is because leading companies constantly look to diversify their revenue base in the face of dwindling sales of their high-profile drugs. Acquisitions also make sense as developing a drug/technology from scratch is costly and risky. In April, pharma giant Johnson & Johnson acquired Intra-Cellular Therapies for approximately $14.6 billion and added antidepressant drug, Caplyta, to its neuroscience portfolio. Swiss pharma bigwig Novartis NVS, too, has been on an acquisition spree. Novartis is all set to acquire San Diego-based clinical-stage biopharmaceutical company Regulus Therapeutics to strengthen its renal disease portfolio. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States. SpringWorks Therapeutics, a U.S.-based biopharma company, has a portfolio that comprises a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. Potential Deals We expect M&A activity to accelerate further in 2025, given the massive cash reserve owned by major pharma and biotech companies. These companies will also look to utilize innovative technology to develop breakthrough treatments rapidly as the landscape evolves. Moreover, smaller biotechs often lack the necessary funds to successfully develop a drug and commercialize thereafter. The recent spotlight on the usage of AI technology for drug discovery should lure investment in this industry. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
Intelligent Bio Solutions (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25
The company's non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates. Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings. INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity. The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety. INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies ( The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for… Read More>> NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications
Globe and Mail
5 hours ago
- Globe and Mail
Insider Buying and Options Surge Spark Bullish Interest in UnitedHealth (UNH)
UnitedHealth Group (UNH) is drawing attention from traders after a spike in call option activity and notable insider buying. Despite the stock being down nearly 40% year-to-date, a weaker-than-expected Q1 earnings report, and a softer outlook, recent activity suggests growing confidence in a potential recovery. Confident Investing Starts Here: Heightened Activity Signals Bullish Sentiment On Thursday, more than 162,000 call options were traded on UNH. That's a 29% jump compared to the stock's typical daily call volume of around 126,000. This level of activity often reflects bullish expectations from traders anticipating upward price movement. Insiders are also showing conviction. On May 14, Director John H. Noseworthy purchased 300 shares at an average price of $312.16. Six days later, CEO Stephen Hemsley bought 86,700 shares at an average of $288.57 per share, totaling over $25 million. In total, insiders have acquired 109,408 shares over the past 90 days, worth approximately $31.6 million. Insider buying of this scale often signals confidence in long-term value. Institutional investors have also been increasing their exposure to these assets. Vanguard, Wellington Management, and Norges Bank all added to their positions last quarter. Institutional ownership now stands at 87.9%, highlighting continued support from long-term holders. Stock Rebounds Slightly as Fundamentals Show Mixed Signals The stock closed Friday at $303.22, up 2.49% on the day. It remains far below its 52-week high of $630.73 and just above the recent low of $248.88. At current levels, UNH has a market cap of about $275 billion, a P/E ratio of 14.11, and a dividend yield of 2.84%. The company recently raised its quarterly dividend to $2.21 per share. UnitedHealth posted Q1 revenue of $109.6 billion, slightly below consensus estimates. Earnings per share came in at $7.20, missing expectations of $7.29. While analysts still expect full-year EPS of $29.54, several firms have lowered their price targets in response to the softer results and rising sector concerns. Options market data reinforces the bullish tilt. The put/call ratio is 0.48, indicating more call buying than put buying. This ratio suggests traders are positioning for a potential rebound in the near term. In summary, while UnitedHealth continues to face pressure from weaker earnings and macroeconomic headwinds, the surge in call option activity, insider buying, and strong institutional support indicate renewed investor interest. Is UNH a Good Stock to Buy Right Now? According to The Street's analysts, UnitedHealth is a Moderate Buy. The average UNH price target is $369.73, implying a 21.93% upside. See more UNH analyst ratings Disclaimer & Disclosure Report an Issue
